Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 267 shares, a decrease of 93.5% from the August 31st total of 4,133 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 53,604 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Monday, July 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Addex Therapeutics Stock Performance

ADXN stock traded up $0.01 on Thursday, hitting $3.46. 7,865 shares of the company’s stock were exchanged, compared to its average volume of 40,560. The firm has a 50 day moving average price of $4.67 and a two-hundred day moving average price of $5.85. Addex Therapeutics has a 12-month low of $3.10 and a 12-month high of $11.97. The stock has a market cap of $4.26 million, a P/E ratio of -0.58 and a beta of 1.47.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd. (NASDAQ: ADXN) is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland. The company develops small-molecule medicines that act through allosteric modulation, a drug-discovery approach designed to influence G protein-coupled receptors (GPCRs) at sites distinct from where naturally occurring signaling molecules bind.

Addex’s research has focused primarily on treatments for disorders of the central nervous system. Its development programs have included ADX71149, an investigational positive allosteric modulator of the metabotropic glutamate receptor 2 (mGluR2), and other compounds targeting neurological and psychiatric conditions.